- Home
- ROOT vs ANAB Comparison
ROOT vs ANAB Comparison
Compare ROOT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | ANAB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ROOT | ANAB |
|---|---|---|
| Price | $72.85 | $47.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $125.80 | $59.90 |
| AVG Volume (30 Days) | 243.7K | ★ 418.9K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $1,446,800,000.00 | $169,467,000.00 |
| Revenue This Year | $29.96 | $135.45 |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | $21.61 | ★ N/A |
| Revenue Growth | 38.50 | ★ 196.42 |
| 52 Week Low | $68.08 | $12.21 |
| 52 Week High | $181.14 | $52.47 |
Technical Indicators
Market Signals| Indicator | ROOT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 57.80 |
| Support Level | $71.25 | $46.89 |
| Resistance Level | $74.54 | $52.47 |
| Average True Range (ATR) | 3.02 | 2.14 |
| MACD | -0.49 | -0.34 |
| Stochastic Oscillator | 6.79 | 40.35 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).